An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. - Wikidata - wikimedia - TriplyDB

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

http://www.wikidata.org/entity/Q45874701

about

New developments in the management of moderate-to-severe hemophilia B siRNA Versus miRNA as Therapeutics for Gene Silencing Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection The current state of adverse event reporting in hemophilia.Visualization of self-delivering hydrophobically modified siRNA cellular internalization.siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2.Hemophilia Care in the Pediatric Age.The notorious R.N.A. in the spotlight - drug or target for the treatment of disease CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.Design and characterization of an APC-specific serpin for the treatment of hemophilia.Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.New products for the treatment of haemophilia.Identification and function probing of an antithrombin IIIβ conformation-specific antibody.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.Haemophilia treatment in 2030.The utility of thromboelastography in inherited and acquired bleeding disorders.Rethinking events in the haemostatic process: role of factor V and TFPI.Emerging drugs for the treatment of hemophilia A and B.2017 Clinical trials update: Innovations in hemophilia therapy.The chemical evolution of oligonucleotide therapies of clinical utility.Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy.Oral nucleic acid therapy using multicompartmental delivery systems.An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.Extended half-life clotting factor concentrates: results from published clinical trials.Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide.5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo.Harnessing human ADAR2 for RNA repair - Recoding a PINK1 mutation rescues mitophagy.The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany.Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.Alternative therapies for the management of inhibitors.Novel approaches to hemophilia therapy: successes and challenges.Future of Haemophilia Research in India.Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers.Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.

P2860

Q26751323-C8C67040-B016-445D-9753-ED90B8DE1243 Q26786876-3B59C1FC-5891-4C03-A54A-6437A761EB84 Q26795919-3680FA3D-BAC0-4197-9838-44939FC43EF6 Q30239952-5F1F6D54-4D1A-40CC-A3A4-95EBBF91A827 Q30834506-8B8AC9FD-3188-4257-A808-080D5EBB9D60 Q33558210-E7241472-0936-4D5E-AF9E-C399731BCA5C Q33737259-F7DC715E-DB91-4690-A8AE-EBA4B4B59015 Q33739733-4FDC68EE-677B-438A-8F0B-473906D0432C Q33830117-7B6D4DB4-9E0B-43B7-BBB6-51BA69299653 Q36176667-0D9D4065-79DC-49A2-9B59-11593FCADCA3 Q36337979-D8457785-E204-48CB-BBF2-9AA6FBB24C5F Q36775577-EC59BCDB-846E-49F8-A951-563317B33E2A Q36981555-CBD8127B-CA22-443E-BE0A-32827DB981B6 Q37718173-AD9305CA-52F3-4150-8531-5163C3987425 Q38574414-5A9C3746-A0FC-4F79-A525-B467C9940F87 Q38604626-2C27BDA7-62EB-423F-860E-60A689939CB0 Q38818678-06C63347-0B32-4C8C-877B-0D0162BBB4B7 Q38828174-1012D848-5A47-493B-AFD5-28841A8E6F21 Q38842671-1CF49BB9-3342-4CFD-9396-45384E9CF5C1 Q38855599-CAC5D61A-958E-4BFD-85E0-83740930184C Q38894147-5AD92050-C38C-4CC1-A348-A05EC50615EF Q38933707-46D07E47-EAFE-489E-9B2A-6571191C0DBA Q38937725-88D28AC6-5F7C-415E-BB42-98576DA1E8E3 Q39154511-B47403AB-5227-45F9-9F85-FFC36CAD78F6 Q39175404-37A680B1-5BC2-4B40-B20A-C9CB9DDEA65E Q39330117-89B75B39-9F67-4EB5-AF0C-A821B0B6E9EE Q39586687-B3CA0FE6-7AE7-441B-A37E-628E7E83A878 Q39609294-4BD24327-5FE9-4212-9992-2E0691B5BC35 Q41449580-0AFE31C7-5A51-41F9-BC27-A14B4B78A10B Q41510865-39EA8F43-1DB2-4221-99A6-30D5B3DC90D5 Q41982249-519D2742-D628-4A20-B251-9779C5DBD44A Q45232152-37E54E94-B00A-46C1-AA88-10699BE0314B Q45855101-FCCDC07C-8945-4CD2-A507-C3D425E92B85 Q45856195-3DF57C76-A566-4A81-9D66-8145F4EDC620 Q45873013-6271B945-BA9B-49E0-9613-3BB48DA7C5F9 Q45873621-115F5B89-38F3-4C40-8C9F-BA499A16ED75 Q45880852-5CF46242-B1EC-4245-9C08-85F0A8B3907A Q46118467-DC3DD6D2-5D9B-47B1-B8EE-8E2280987310 Q46291725-C5D55895-1B27-44A5-BE6B-618677772BD1 Q47363697-CE31B5E7-4E81-4BD8-979B-0E535713FA80

P2860

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

http://www.wikidata.org/entity/Q45874701

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

An RNAi therapeutic targeting ...... mote hemostasis in hemophilia.

@en

An RNAi therapeutic targeting ...... mote hemostasis in hemophilia.

@nl

type

label

An RNAi therapeutic targeting ...... mote hemostasis in hemophilia.

@en

An RNAi therapeutic targeting ...... mote hemostasis in hemophilia.

@nl

prefLabel

An RNAi therapeutic targeting ...... mote hemostasis in hemophilia.

@en

An RNAi therapeutic targeting ...... mote hemostasis in hemophilia.

@nl

P1433

Q45874701-EDF34E9D-D353-4FA8-96BA-6784AC0AF213

P1476

Q45874701-139750A9-3295-4DB8-A7BD-4EECEB93376A

P2093

Q45874701-018D5B76-2A71-43A7-9038-9D174A48C620

Q45874701-1723EBF4-FDE4-4622-929A-16071C0B12F1

Q45874701-31BFBA89-2FCA-4036-81A9-2A51E04B7530

Q45874701-3233DFD9-8701-40BF-99BE-7A57236BD366

Q45874701-3290281D-C2D2-4E8F-A1ED-AB4E1FCE31C9

Q45874701-3CCBB770-B642-4334-82DD-DEDF86B73D52

Q45874701-3D619749-2531-4DA9-A404-6F2E6909E3E6

Q45874701-4A707DB9-E3C5-433E-93A4-713A6F82D527

Q45874701-4E20C278-18D6-45A4-8860-96A43D197996

Q45874701-4E9EA1FA-396F-484A-A2DB-BA9750466BA9

P2860

Q45874701-030F686C-D24D-4ADB-A9CD-5981B7FE026B

Q45874701-08333A8B-3B5F-4F40-8474-F3A0567663D8

Q45874701-181FFE44-97A3-4326-887B-B9FAF0073FDE

Q45874701-1B1D301C-AF4F-46AC-A1BD-C3454D4FBB6E

Q45874701-284EE73E-AB19-4F37-8824-65EB4B09EEB1

Q45874701-3A94A6B4-49CD-4DA4-AF95-B0397B0066DB

Q45874701-3ED46714-C56F-492C-BED1-2F582AEFE8FE

Q45874701-4EFAC943-FF93-4551-9C6C-6CCCB36BEE1D

Q45874701-51EFFB12-28A8-4C1A-B768-B7BF0D2485E2

Q45874701-5373AED5-0E79-4D00-8EA9-4329C33CFE92

P2888

Q45874701-B74D2280-D65B-4389-B6B0-D8BCB22426FE

P304

Q45874701-F657B4FA-8DA9-45B6-BD01-1856424218D3

P31

Q45874701-411B46A7-229B-4F72-9503-6DC1E497B6B2

P356

Q45874701-50EFF0CD-8CE5-4996-A953-8A6FB89395D6

P407

Q45874701-44C4AC02-4E35-4BF1-A697-88970A46F19E

P433

Q45874701-78BAD5AC-580A-49DA-971E-5E213CC5409C

P478

Q45874701-A3BEE090-8A64-4631-B6AB-AA6F80E3CE4C

P50

Q45874701-485EE5F5-84F4-4311-B835-B9BB62698F5F

Q45874701-BD57F955-9315-4727-A33D-2B666D6199C5

P577

Q45874701-6061FD6A-1018-49DE-9130-0C894CED6399

P6179

Q45874701-1DF38AD5-D294-41FF-8B37-3AD6A53C8E54

P698

Q45874701-B551B94A-8100-413C-95B2-AD5AFAEB23AC

P921

Q45874701-5FB8D858-6875-40B2-804B-55E07226CA28

P356

P1433

Nature Medicine

P1476

An RNAi therapeutic targeting ...... omote hemostasis in hemophilia

@en

P2093

Akin Akinc

http://www.w3.org/2001/XMLSchema#string

Alexander V Kel'in

http://www.w3.org/2001/XMLSchema#string

Alfica Sehgal

http://www.w3.org/2001/XMLSchema#string

Amy R Simon

http://www.w3.org/2001/XMLSchema#string

Benny Sorensen

http://www.w3.org/2001/XMLSchema#string

Brian Cooley

http://www.w3.org/2001/XMLSchema#string

Don Foster

http://www.w3.org/2001/XMLSchema#string

Harsha Prabhala

http://www.w3.org/2001/XMLSchema#string

Husain Attarwala

http://www.w3.org/2001/XMLSchema#string

Jayaprakash K Nair

http://www.w3.org/2001/XMLSchema#string

P2860

A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state

Calibrated automated thrombin generation measurement in clotting plasma

Factor V Leiden improves in vivo hemostasis in murine hemophilia models.

Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice

World distribution of factor V Leiden.

A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Mutation in blood coagulation factor V associated with resistance to activated protein C.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Modifier genes in haemophilia: their expansion in the human genome.

P2888

P304

492-497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3847

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014623450

http://www.w3.org/2001/XMLSchema#string

P698

25849132

http://www.w3.org/2001/XMLSchema#string

P921